newsfilter
← Latest News
GlobeNewswire·

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT